Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Depreciation and Depletion (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Depreciation and Depletion for 7 consecutive years, with $51000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion fell 86.89% to $51000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, down 56.52% year-over-year, with the annual reading at $1.0 million for FY2025, 56.52% down from the prior year.
  • Depreciation and Depletion hit $51000.0 in Q4 2025 for Ligand Pharmaceuticals, down from $172000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $736000.0 in Q3 2024 to a low of $51000.0 in Q4 2025.